Cholesterol-containing reconstituted high-density lipoprotein nanoparticles
Reconstituted high-density lipoprotein nanoparticles address the challenge of drug delivery across the blood-brain barrier by inducing cholesterol efflux and apoptosis in cancer cells, offering a therapeutic approach for glioblastoma, pancreatic cancer, and Alzheimer's disease.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- MEPSGEN CO LTD
- Filing Date
- 2024-05-03
- Publication Date
- 2026-05-25
AI Technical Summary
Current cancer treatments, particularly for glioblastoma and pancreatic cancer, face challenges due to the low permeability of the blood-brain barrier and dysregulation of cholesterol homeostasis, leading to ineffective drug delivery and excessive intracellular cholesterol accumulation, which complicates treatment and prognosis.
Development of reconstituted high-density lipoprotein (rHDL) nanoparticles containing cholesterol and apolipoprotein E, which can cross the blood-brain barrier and induce cholesterol efflux by targeting low-density lipoprotein receptors (LDLR), thereby promoting cancer cell death.
The rHDL nanoparticles effectively treat glioblastoma and pancreatic cancer by increasing ABCA1 expression, enhancing cholesterol efflux, and inducing apoptosis, while also being applicable for Alzheimer's disease treatment, with the ability to cross the blood-brain barrier without toxicity.
Smart Images
Figure 2026516447000001_ABST